Jim Cramer Says Eli Lilly Isn’t a ‘One Trick Pony’ After FDA Endorsement

Bullish on Eli Lilly: Cramer is confident about Eli Lilly, highlighting its success in weight loss and diabetes drugs, and potential growth with its new Alzheimer’s treatment.

Alzheimer’s Drug Approval: An FDA advisory panel unanimously recommended Eli Lilly’s Alzheimer’s drug, donanemab, moving it closer to full approval.

Market Potential: Donanemab targets amyloid plaques to slow Alzheimer’s progression, offering new hope for a disease with limited treatment options.

Market Uncertainty: While some analysts see Biogen and Eisai’s Leqembi as safer, Cramer views the advisory panel’s recommendation as a positive step for Eli Lilly.

Future Growth: Cramer believes Eli Lilly, currently valued at $823 billion, could reach a trillion-dollar valuation, driven by its diverse and innovative drug pipeline.

Summary:
Jim Cramer remains bullish on Eli Lilly, citing the company’s potential for growth beyond its weight loss and diabetes drugs, particularly with the FDA advisory panel’s endorsement of its Alzheimer’s drug, donanemab. He sees this as a sign of Eli Lilly’s diverse and promising pipeline, reinforcing its strong market position.